Mónica Arnedos

Rb-driven transcription limits its tumour-suppressive effects in breast cancer

April C. Watt, Antonio Ahn, Catherine Blyth, Julia R. Dixon-Douglas et autres

au, fr, us (code pays fourni par la source)

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial

Judy E. Garber, D. Cameron, C. Campbell, G. Yothers et autres

us, gb, sg, be, pl, es, fr, tw, se, de, it, kr, jp, ch, is, ar, au, at, ca, nl, cn, ie (code pays fourni par la source)

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer

Sara A. Hurvitz, Rachel M. Layman, Giuseppe Curigliano, Fabrice André et autres

us, it, fr, kr, mx, ar, au, lu, es, gb (code pays fourni par la source)

Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database

William Jacot, P. Macouillard, Suyuan Zhang, Danalyn Byng et autres

Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort

Romain Varnier, David Pérol, William Jacot, Audrey Mailliez et autres

fr (code pays fourni par la source)

587P Recent nationwide overall survival trends across subtypes in 33,044 patients with metastatic breast cancer in the French ESME cohort

Paul Cottu, A. Antoine, W. Jacot, V. Diéras et autres

fr (code pays fourni par la source)

515P Real world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer in the ESME-MBC cohort

Romain Varnier, David Pérol, W. Jacot, A. Mailliez et autres

fr (code pays fourni par la source)

Abstract P2-03-29: Upregulation of senescence signatures and interferon-signalling after short-term pre-operative CDK4/6 inhibitor – gene expression analysis from the POP and ABC-POP trials

Julia Dixon‐Douglas, Bastien Job, Mónica Arnedos, Alicia Tran-Dien et autres

Abstract P3-08-03: Trends in Presentation of HER2+ Breast Cancer: A Retrospective study of De Novo Versus Recurrent Metastatic Breast Cancer (MBC) in the Real-World French National ESME Cohort (2008-2022)

Thomas Grinda, Amélie Lusque, Stefania Morganti, Aurélie Bertaut et autres

Abstract P2-09-23: Differential outcomes of patients with HR-positive/HER2-negative metastatic breast cancer and a pathogenic BRCA1/2 or PALB2 variant under first line CDK4/6 inhibition

Timothé Guinel, Amélie Lusque, Audrey Mailliez, Vincent Massard et autres

Efficacy of tucatinib, trastuzumab, and capecitabine (TTC) following trastuzumab-deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (MBC): Updated results and subgroup analyses from the UNICANCER multicenter retrospective cohort.

Jean‐Sébastien Frenel, Jean Zeghondy, Catherine Guérin‐Charbonnel, Audrey Mailliez et autres

fr (code pays fourni par la source)

Short-term pre-operative durvalumab (MEDI 4736) in early small triple-negative breast cancer patients (POP-Durva).

Joana Ribeiro, Julia Dixon‐Douglas, Isabelle Pic, Quentin Blampey et autres

au, fr (code pays fourni par la source)